Known targets — ChEMBL curated mechanism
ABCC8ACEADORA1ADORA2AADORA2BADORA3ALDH5A1ALOX5ALOX5APATP4AATP4BBRAFCA1CA12CA2CA4CYSLTR1DHFRDPEP1EDNRAEDNRBESR2F10FDPSFGF1GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTGNRHRGSC1HMGCRIMPDH1IMPDH2KCNJ11LY96NOD2NR3C1NS3NS4ANS5bP2RY1P2RY12P2RY2P2RY4P2RY6PBP2XPDE3APDE3BPDE4APDE4BPDE4CPDE4DPDK1PDK2PDK3PDK4PPARGPPATPTGIRPTGS1PTGS2RAF1RYR1RYR3SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASERPINC1SLC12A1SLC12A3SYKTHRATHRBTLR3TLR4TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYMSVKORC1XDHblablaIMP-1blaOXA-33blaOXA-58blaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAfolPfolP1ftsIfusAgaggyrAgyrBmecAmrcAmrcBmrdApbp1apbp1bpbp2pbp2apbp2bpbp3pbp4pbpApbpBpbpCpbpFpolponBrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpoArpoBrpoCrpoZrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 known ✓ | P00918 | 2/20 | 0.96 |
| ▸ | CA1 known ✓ | P00915 | 2/20 | 0.63 |
| ▸ | NFKB1 | P19838 | 3/20 | 0.67 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.67 |
| ▸ | TSHR | P16473 | 2/20 | 0.67 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.67 |
| ▸ | GPR84 | Q9NQS5 | 4/20 | 0.55 |
| ▸ | GRIK1 | P39086 | 2/20 | 0.48 |
| ▸ | GRIK2 | Q13002 | 2/20 | 0.48 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | LCK | P06239 | 1/20 | 0.47 |
| ▸ | PPARD | Q03181 | 1/20 | 0.47 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.47 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.47 |
| ▸ | CES2 | O00748 | 3/20 | 0.46 |
| ▸ | CES1 | P23141 | 3/20 | 0.46 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.46 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15387978 | 1.00 | CA2 (0.96) | CA2NFKB1CYP3A4TSHRNPSR1 | |
| SCHEMBL5496573 | 1.00 | CA2 (0.96) | CA2NFKB1CYP3A4TSHRNPSR1 | |
| SCHEMBL4254221 | 1.00 | CA2 (0.96) | CA2NFKB1CYP3A4TSHRNPSR1 | |
| SCHEMBL1963319 | 1.00 | CA2 (0.96) | CA2NFKB1CYP3A4TSHRNPSR1 | |
| SCHEMBL15387890 | 1.00 | CA2 (0.96) | CA2NFKB1CYP3A4TSHRNPSR1 | |
| SCHEMBL15387941 | 1.00 | CA2 (0.96) | CA2NFKB1CYP3A4TSHRNPSR1 | |
| SCHEMBL6608444 | 1.00 | CA2 (0.96) | CA2NFKB1CYP3A4TSHRNPSR1 | |
| SCHEMBL689372 | 1.00 | CA2 (0.96) | CA2NFKB1CYP3A4TSHRNPSR1 | |
| SCHEMBL15387920 | 1.00 | CA2 (0.96) | CA2NFKB1CYP3A4TSHRNPSR1 | |
| SCHEMBL5704847 | 1.00 | CA2 (0.96) | CA2NFKB1CYP3A4TSHRNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 159 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122080093-A | Compounds effective in treating liver toxicity and fatty liver disease and uses thereof | — | 2026-05-26 | — | — | CN | claimed |
| US-20260115155-A1 | STABLE FORMS OF CAPSAICIN PALMITATE FOR THE TREATMENT OF PAIN | CHORDA PHARMA INC (US) | 2026-04-30 | — | — | US | claimed |
| CN-117404060-A | Analysis method for judging oil well blockage reason and composite blockage removing liquid thereof | 中国石油天然气集团有限公司 | 2024-01-16 | — | — | CN | claimed |
| CN-116133639-A | Formulations and methods for treating inflammatory diseases | 维奥梅治疗公司 | 2023-05-16 | — | — | CN | claimed |
| US-20230144779-A1 | FORMULATIONS AND METHOD FOR TREATMENT OF INFLAMMATORY DISEASES | VYOME THERAPEUTICS INC. (US) | 2023-05-11 | — | — | US | claimed |
| CN-115058137-A | Photocuring stainless steel powder slurry | 扬州海昌新材股份有限公司 | 2022-09-16 | — | — | CN | claimed |
| WO-2021124301-A1 | FORMULATIONS AND METHOD FOR TREATMENT OF INFLAMMATORY DISEASES | VYOME THERAPEUTICS INC. (US) | 2021-06-24 | — | — | WO | claimed |
| CN-109419779-B | Sotalol hydrochloride preparation | 鲁南制药集团股份有限公司 | 2021-05-25 | — | — | CN | claimed |
| CN-106009778-B | A kind of dedicated bloom anti-impact wet method super-fine raw powder's production technology of appliance shell material | 江西广源化工有限责任公司 | 2019-05-31 | — | — | CN | claimed |
| CN-109419779-A | A kind of Betapace | 鲁南制药集团股份有限公司 | 2019-03-05 | — | — | CN | claimed |
| CN-104274551-A | Potentilla anserine and herpetospermum seed chewable tablet and preparation method thereof | SUZHOU TIANLING CHINESE TRADITIONAL MEDICINE SLICE CO LTD | 2015-01-14 | — | — | CN | claimed |
| CN-104274705-A | Sobering and liver protecting chewable tablet and preparation method thereof | SUZHOU TIANLING CHINESE TRADITIONAL MEDICINE SLICE CO LTD | 2015-01-14 | — | — | CN | claimed |
| US-20090197855-A1 | PHARMACEUTICAL COMPOSITIONS OF CEFDINIR | LUPIN LIMITED (IN) | 2009-08-06 | — | — | US | claimed |
| US-20090082325-A1 | Cefidinir Oral Suspension | ABBOTT LABORATORIES (US) | 2009-03-26 | — | — | US | claimed |
| US-20080139528-A1 | Cefdinir oral suspension | ABBOTT LABORATORIES | 2008-06-12 | — | — | US | claimed |
| WO-2007125541-A1 | PHARMACEUTICAL COMPOSITIONS OF CEFDINIR | LUPIN LIMITED (IN) | 2007-11-08 | — | — | WO | claimed |
| US-20070249576-A1 | Cefdinir Oral Suspension | PUJARA CHETAN P | 2007-10-25 | — | — | US | claimed |
| EP-1708681-A1 | CEFDINIR ORAL SUSPENSION | ABBOTT LABORATORIES (US) | 2006-10-11 | — | — | EP | claimed |
| WO-2005060936-A1 | CEFDINIR ORAL SUSPENSION | ABBOTT LABORATORIES (US) | 2005-07-07 | — | — | WO | claimed |
| US-20050131079-A1 | Cefdinir oral suspension | ABBOTT LABORATORIES | 2005-06-16 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230144779-A1 | FORMULATIONS AND METHOD FOR TREATMENT OF INFLAMMATORY DISEASES | UACA, TNF, TPMT | CA2 266/4885CA1 1526/4885NFKB1 155/4885 |
| US-20260115155-A1 | STABLE FORMS OF CAPSAICIN PALMITATE FOR THE TREATMENT OF PAIN | TRPV1, SPTLC3, FFAR3 | CA2 530/4885CA1 1707/4885NFKB1 860/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.